Department of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
J Mol Med (Berl). 2012 Apr;90(4):413-26. doi: 10.1007/s00109-011-0828-1. Epub 2011 Nov 15.
Pattern recognition scavenger receptor SRA/CD204, primarily expressed on specialized antigen-presenting cells (APCs), including dendritic cells (DCs) and macrophages, has been implicated in multiple physiological and pathological processes, including atherosclerosis, Alzheimer's disease, endotoxic shock, host defense, and cancer development. SRA/CD204 was also recently shown to function as an attenuator of vaccine response and antitumor immunity. Here, we, for the first time, report that SRA/CD204 knockout (SRA(-/-)) mice developed a more robust CD4(+) T cell response than wild-type mice after ovalbumin immunization. Splenic DCs from the immunized SRA(-/-) mice were much more efficient than those from WT mice in stimulating naïve OT-II cells, indicating that the suppressive activity of SRA/CD204 is mediated by DCs. Strikingly, antigen-exposed SRA(-/-) DCs with or without lipopolysaccharide treatment exhibited increased T-cell-stimulating activity in vitro, which was independent of the classical endocytic property of the SRA/CD204. Additionally, absence of SRA/CD204 resulted in significantly elevated IL12p35 expression in DCs upon CD40 ligation plus interferon gamma (IFN-γ) stimulation. Molecular studies reveal that SRA/CD204 inhibited the activation of STAT1, mitogen activated protein kinase p38, and nuclear factor-kappa B signaling activation in DCs treated with anti-CD40 antibodies and IFN-γ. Furthermore, splenocytes from the generated SRA(-/-) OT-II mice showed heightened proliferation upon stimulation with OVA protein or MHC-II-restricted OVA(323-339) peptide compared with cells from the SRA(+/+) OT-II mice. These results not only establish a new role of SRA/CD204 in limiting the intrinsic immunogenicity of APCs and CD4(+) T cell activation but also provide additional insights into the molecular mechanisms involved in the immune suppression by this molecule.
模式识别清道夫受体 SRA/CD204 主要表达于专业抗原呈递细胞(APCs),包括树突状细胞(DCs)和巨噬细胞,其在多种生理和病理过程中发挥作用,包括动脉粥样硬化、阿尔茨海默病、内毒素休克、宿主防御和癌症发展。SRA/CD204 最近也被证明是疫苗反应和抗肿瘤免疫的抑制剂。在这里,我们首次报道,在卵清蛋白免疫后,SRA/CD204 敲除(SRA(-/-))小鼠比野生型(WT)小鼠产生更强烈的 CD4(+)T 细胞反应。与 WT 小鼠相比,来自免疫 SRA(-/-)小鼠的脾 DC 更有效地刺激幼稚 OT-II 细胞,表明 SRA/CD204 的抑制活性是通过 DC 介导的。引人注目的是,即使在 LPS 处理下,抗原暴露的 SRA(-/-)DC 显示出体外更强的 T 细胞刺激活性,这与 SRA/CD204 的经典内吞特性无关。此外,在 CD40 配体加干扰素 γ(IFN-γ)刺激下,SRA/CD204 缺失导致 DC 中 IL12p35 的表达显著升高。分子研究表明,SRA/CD204 抑制了经抗 CD40 抗体和 IFN-γ 处理的 DC 中 STAT1、丝裂原激活蛋白激酶 p38 和核因子-κB 信号通路的激活。此外,与 SRA(+/+)OT-II 小鼠的细胞相比,来自生成的 SRA(-/-)OT-II 小鼠的脾细胞在受到 OVA 蛋白或 MHC-II 限制性 OVA(323-339)肽刺激时表现出更高的增殖。这些结果不仅确立了 SRA/CD204 在限制 APC 和 CD4(+)T 细胞激活固有免疫原性中的新作用,而且为该分子参与免疫抑制的分子机制提供了更多的见解。